Bekir M. Hacioglu

Edirne, 22000, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Assessment of new pathological markers in early stage colon cancer: Insights and limitations.

Assessment of new pathological markers in early stage colon cancer: Insights and limitations.

Journal: World journal of gastrointestinal oncology

Published: September 10, 2024

Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium.

Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium.

Journal: Therapeutic advances in medical oncology

Published: August 23, 2024

Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Journal: Clinical genitourinary cancer

Published: July 17, 2024

Diffusion tensor imaging: survival analysis prediction in breast cancer patients.

Diffusion tensor imaging: survival analysis prediction in breast cancer patients.

Journal: Radiologie (Heidelberg, Germany)

Published: May 11, 2023

The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.

The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: July 16, 2021

Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma.

Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma.

Journal: Tumori

Published: February 24, 2021

Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.

Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 19, 2020

Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group.

Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: May 26, 2019

A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).

A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: April 04, 2019

Invasive Pleomorphic Lobular Histology Is an Adverse Prognostic Factor on Survival in Patients with Breast Cancer.

Invasive Pleomorphic Lobular Histology Is an Adverse Prognostic Factor on Survival in Patients with Breast Cancer.

Journal: The American surgeon

Published: April 21, 2017

K-RAS and N-RAS mutations in testicular germ cell tumors.

K-RAS and N-RAS mutations in testicular germ cell tumors.

Journal: Bosnian journal of basic medical sciences

Published: November 01, 2016

Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.

Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.

Journal: Anti-cancer drugs

Published: October 22, 2016

Showing 1-12 of 16

Last Updated: 09/26/2026